This protocol applies to patients identified as high risk of tumour lysis syndrome — a population in whom active prophylaxis is indicated from the outset rather than a reactive approach. Prompt recognition of this risk category determines the appropriate intervention pathway.
The protocol combines intravenous hydration with prophylactic rasburicase. Specific dosing and monitoring requirements differ between adult and paediatric patients, and the need for repeat dosing is guided by ongoing laboratory assessment.